Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

112 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Drug Tolerant Anti-drug Antibody Assay for Infliximab Treatment in Clinical Practice Identifies Positive Cases Earlier.
Kharlamova N, Hermanrud C, Dunn N, Ryner M, Hambardzumyan K, Vivar Pomiano N, Marits P, Gjertsson I, Saevarsdottir S, Pullerits R, Fogdell-Hahn A. Kharlamova N, et al. Among authors: saevarsdottir s. Front Immunol. 2020 Jul 21;11:1365. doi: 10.3389/fimmu.2020.01365. eCollection 2020. Front Immunol. 2020. PMID: 32793189 Free PMC article.
Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial.
Hambardzumyan K, Bolce R, Saevarsdottir S, Cruickshank SE, Sasso EH, Chernoff D, Forslind K, Petersson IF, Geborek P, van Vollenhoven RF. Hambardzumyan K, et al. Among authors: saevarsdottir s. Ann Rheum Dis. 2015 Jun;74(6):1102-9. doi: 10.1136/annrheumdis-2013-204986. Epub 2014 May 8. Ann Rheum Dis. 2015. PMID: 24812287 Free PMC article. Clinical Trial.
Brief report: enhancement of patient recruitment in rheumatoid arthritis clinical trials using a multi-biomarker disease activity score as an inclusion criterion.
van Vollenhoven RF, Bolce R, Hambardzumyan K, Saevarsdottir S, Forslind K, Petersson IF, Sasso EH, Hwang CC, Segurado OG, Geborek P. van Vollenhoven RF, et al. Among authors: saevarsdottir s. Arthritis Rheumatol. 2015 Nov;67(11):2855-60. doi: 10.1002/art.39274. Arthritis Rheumatol. 2015. PMID: 26213309 Free PMC article.
Association of a multibiomarker disease activity score at multiple time-points with radiographic progression in rheumatoid arthritis: results from the SWEFOT trial.
Hambardzumyan K, Bolce RJ, Saevarsdottir S, Forslind K, Wallman JK, Cruickshank SE, Sasso EH, Chernoff D, van Vollenhoven RF. Hambardzumyan K, et al. Among authors: saevarsdottir s. RMD Open. 2016 Mar 1;2(1):e000197. doi: 10.1136/rmdopen-2015-000197. eCollection 2016. RMD Open. 2016. PMID: 26958364 Free PMC article.
Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis.
Quistrebert J, Hässler S, Bachelet D, Mbogning C, Musters A, Tak PP, Wijbrandts CA, Herenius M, Bergstra SA, Akdemir G, Johannesson M, Combe B, Fautrel B, Chollet-Martin S, Gleizes A, Donnellan N, Deisenhammer F, Davidson J, Hincelin-Mery A, Dönnes P, Fogdell-Hahn A, De Vries N, Huizinga T, Abugessaisa I, Saevarsdottir S, Hacein-Bey-Abina S, Pallardy M, Broët P, Mariette X; ABIRISK Consortium. Quistrebert J, et al. Among authors: saevarsdottir s. Semin Arthritis Rheum. 2019 Jun;48(6):967-975. doi: 10.1016/j.semarthrit.2018.10.006. Epub 2018 Oct 12. Semin Arthritis Rheum. 2019. PMID: 30420245
Predicting risk for radiographic damage in rheumatoid arthritis: comparative analysis of the multi-biomarker disease activity score and conventional measures of disease activity in multiple studies.
Curtis JR, Brahe CH, Østergaard M, Lund Hetland M, Hambardzumyan K, Saevarsdottir S, Wang X, Flake Ii DD, Sasso EH, Huizinga TW. Curtis JR, et al. Among authors: saevarsdottir s. Curr Med Res Opin. 2019 Sep;35(9):1483-1493. doi: 10.1080/03007995.2019.1585064. Epub 2019 Mar 14. Curr Med Res Opin. 2019. PMID: 30777458
Association of female sex and positive rheumatoid factor with low serum infliximab and anti-drug antibodies, related to treatment failure in early rheumatoid arthritis: results from the SWEFOT trial population.
Hambardzumyan K, Hermanrud C, Marits P, Vivar N, Ernestam S, Wallman JK, van Vollenhoven RF, Fogdell-Hahn A, Saevarsdottir S; SWEFOT study group. Hambardzumyan K, et al. Among authors: saevarsdottir s. Scand J Rheumatol. 2019 Sep;48(5):362-366. doi: 10.1080/03009742.2019.1602670. Epub 2019 Jun 27. Scand J Rheumatol. 2019. PMID: 31244356 Clinical Trial.
112 results